Form 4: TriSalus Life Sciences Director Awarded Stock Options

TriSalus Life Sciences director, Gary B. Gordon, was granted stock options for 41,250 shares on January 29, 2025.

Summary

• Gary B. Gordon, a director at TriSalus Life Sciences, was granted stock options on January 29, 2025.
• The options are for a total of 41,250 shares of common stock.
• The exercise price for these options is $4.89 per share.
• 35,000 of the options vest in three equal annual installments starting January 29, 2025, contingent on continued service.
• The remaining 6,250 options fully vest on the one-year anniversary of the grant date or at the next annual stockholder meeting, whichever is earlier, also contingent on continued service.
• The options expire on January 28, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications or surprises.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.
• The options provide an incentive for the director to contribute to the company's success.

Risks

• The value of the stock options is dependent on the future performance of TriSalus Life Sciences.
• If the share price does not increase above the exercise price, the options may not be valuable to the director.
• The vesting of the options is contingent on the director's continued service, which introduces a risk of forfeiture if they leave the company.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of three years for a portion of the options is typical, as is the one-year vesting for the remaining portion.
• The exercise price of $4.89 is a specific value for this grant and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing the company's value.
• The director benefits from the potential for financial gain if the company's stock price increases.

Key Dates

Keywords

stock options, director, TriSalus Life Sciences, equity, vesting, incentive, compensation